Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma

NCT04502706 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04502706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04502706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Terminated
Start date
November 17, 2020
Completion date
March 31, 2022
Enrollment
9 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma